Literature DB >> 9256282

Prevention of graft coronary arteriosclerosis by antisense cdk2 kinase oligonucleotide.

J Suzuki1, M Isobe, R Morishita, M Aoki, S Horie, Y Okubo, Y Kaneda, Y Sawa, H Matsuda, T Ogihara, M Sekiguchi.   

Abstract

Graft coronary arteriosclerosis, which limits the long-term survival of allograft recipients, is characterized by diffuse intimal thickening composed of proliferative smooth muscle cells. We observed that messenger RNA of the cell cycle regulatory enzyme cyclin-dependent kinase (cdk) 2 kinase, which mediates smooth muscle cell proliferation, was elevated in the thickened intima of coronary arteries of murine heterotopic cardiac allografts. We studied the effects of antisense phosphorothioate oligodeoxynucleotide (ODN) against this enzyme using gene transfer mediated by a hemagglutinating virus of Japan (HVJ)-liposome complex intraluminally delivered to inhibit the intimal hyperplasia. At 30 days after transplantation, antisense cdk2 kinase ODN treatment had dramatically inhibited neointimal formation in the allografts. Expression of vascular cell adhesion molecule-1 was also suppressed by antisense cdk2 kinase. However, these effects were not observed in the sense or scrambled ODN-treated allografts. Thus, an intraluminal administration of antisense ODN directed to a specific cell cycle regulatory gene can inhibit neointimal formation after cardiac transplantation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9256282     DOI: 10.1038/nm0897-900

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  10 in total

1.  Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost.

Authors:  Paola Castagnino; Devashish Kothapalli; Elizabeth A Hawthorne; Tina Xu; Richard K Assoian
Journal:  Prostaglandins Other Lipid Mediat       Date:  2010-05-10       Impact factor: 3.072

2.  Phosphorylation regulates Id3 function in vascular smooth muscle cells.

Authors:  Scott T Forrest; Angela M Taylor; Ian J Sarembock; Demetra Perlegas; Coleen A McNamara
Journal:  Circ Res       Date:  2004-08-19       Impact factor: 17.367

Review 3.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

4.  Expression of cell division cycle 2 kinase transcription in chronically rejected cardiac allografts of nonhuman primates.

Authors:  A Schoenbeck; M Isobe; J Suzuki; M Kato; N Kitazawa; J Amano; M Endoh; M Kawauchi; S Takamoto; M Sekiguchi
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 5.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

6.  Direct in vivo inhibition of the nuclear cell cycle cascade in experimental mesangial proliferative glomerulonephritis with Roscovitine, a novel cyclin-dependent kinase antagonist.

Authors:  J W Pippin; Q Qu; L Meijer; S J Shankland
Journal:  J Clin Invest       Date:  1997-11-15       Impact factor: 14.808

Review 7.  Cardiac allograft vasculopathy: the Achilles' heel of long-term survival after cardiac transplantation.

Authors:  Amandeep Dhaliwal; Vinay Thohan
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

8.  Eotaxin and capping protein in experimental vasculopathy.

Authors:  J Chen; L M Akyürek; B Fellström; P Häyry; L C Paul
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 9.  Nucleic acid drugs for prevention of cardiac rejection.

Authors:  Jun-ichi Suzuki; Mitsuaki Isobe; Ryuichi Morishita; Ryozo Nagai
Journal:  J Biomed Biotechnol       Date:  2009-12-31

10.  A systems biology approach to uncovering pharmacological synergy in herbal medicines with applications to cardiovascular disease.

Authors:  Xia Wang; Xue Xu; Weiyang Tao; Yan Li; Yonghua Wang; Ling Yang
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-29       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.